| Weight Loss ≥ 2 kg | Weight gain ≥ 1 kg | ||
---|---|---|---|---|
 | At any time | Sustained to endpoint | At any time | Sustained to endpoint |
Nizatidine study (n = 67) | 20.9% (n = 14) | 7.5% (n = 5) | 70.2% (n = 47) | 59.7% (n = 40) |
Sibutramine study(n = 42) | 42.9% (n = 18) | 26.2% (n = 11) | 42.9% (n = 18) | 19.1% (n = 8) |
Amantadine study(n = 48) | 39.6% (n = 19) | 33.3% (n = 16) | 56.3% (n = 27) | 37.5% (n = 18) |